In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus (SMWS03)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In an open label, randomized, two-way cross-over study, 32 male healthy regular snus users will be given repeated doses of four different types of portion snus: "General", "Catch", "Catch Mini" and "Catch Dry Mini". Each portion of used snus will be collected and frozen (-20 oC) pending analysis of lead (Pb), cadmium (Cd), nicotine and tobacco specific nitrosamines (TSNAs). Unused snus is collected and deep frozen for analysis and calculation of extracted dose. Calculations of extracted amount of lead, cadmium, nicotine and tobacco specific nitrosamines (TSNAs) respectively, will be done for each type of snus.
| Condition | Intervention | Phase |
|---|---|---|
|
Smoking Cessation Smokeless Tobacco Harm Reduction |
Procedure: Buccal administration of nicotine |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Bio-availability Study Intervention Model: Crossover Assignment Masking: Single Blind (Subject) Primary Purpose: Basic Science |
| Official Title: | In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Four Brands of Swedish 'Snus' in Regular Snus Users. |
- In-vivo extraction of cadmium [ Time Frame: 30 minutes' use ] [ Designated as safety issue: Yes ]Extracted amount = mean of 10 unused sachets - residual amount
- in-vivo extraction of tobacco specific nitrosamines (TSNAs) [ Designated as safety issue: Yes ]Extracted amount = mean of 10 unused sachets - residual amount in used sachet
- In-vivo extraction of lead [ Time Frame: 30 minutes' use ] [ Designated as safety issue: Yes ]Extracted amount = mean of 10 unused sachets - residual amount in one used sachet
- In-vivo extraction of nicotine [ Time Frame: 30 minutes' use ] [ Designated as safety issue: Yes ]Extracted amount = mean of 10 unused sachets - residual amount in one used sachet
| Enrollment: | 32 |
| Study Start Date: | May 2004 |
| Study Completion Date: | April 2005 |
| Primary Completion Date: | August 2004 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: General Portion 1 g pouch |
Procedure: Buccal administration of nicotine
Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
Other Names:
|
| Active Comparator: Catch Licorice Portion 1 g pouch |
Procedure: Buccal administration of nicotine
Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
Other Names:
|
| Active Comparator: Catch Licorice Portion Mini 0.5 g pouch |
Procedure: Buccal administration of nicotine
Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
Other Names:
|
| Active Comparator: Catch Licorice Portion Dry Mini 0.3 g pouch |
Procedure: Buccal administration of nicotine
Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
Other Names:
|
Detailed Description:
Comparisons:
A= "General Portion" 1 g portion snus containing approximately 8 mg nicotine per portion.
B= "Catch Licorice Portion" 1 g portion snus containing approximately 8 mg nicotine per portion.
C= "Catch Licorice Portion Mini" 0.5 g portion snus containing approximately 4 mg nicotine per portion.
D= "Catch Dry Licorice Portion Mini" 0.3 g portion snus containing approximately 4 mg nicotine per portion.
Swedish portion snus will be administered once every hour (4 administrations/brand) and will be kept between the upper lip and the gum for 30 minutes. Preload of own brand each morning.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- non-smokers, 18 to 50 years of age.
- Habitual use of > 7 portions snus daily since minimum 1 year.
- Healthy according to the health declaration and interview.
- Written informed consent given.
Exclusion Criteria:
- Concurrent participation in another clinical trial.
- History of allergy.
- History of allergy.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Erik Lunell, MD, PhD, CROel AB |
| ClinicalTrials.gov Identifier: | NCT01369693 History of Changes |
| Other Study ID Numbers: | 2004/3 |
| Study First Received: | November 16, 2010 |
| Last Updated: | June 8, 2011 |
| Health Authority: | Sweden: Regional Ethical Review Board |
Keywords provided by Contract Research Organization el AB:
|
smokeless tobacco Nicotine Cadmium lead Tobacco Specific Nitrosamines |
Additional relevant MeSH terms:
|
Smoking Habits Lobeline Nicotine Nicotine polacrilex Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Respiratory System Agents Therapeutic Uses Central Nervous System Stimulants Central Nervous System Agents |
ClinicalTrials.gov processed this record on June 18, 2013